Get the Stockscreener App
10.94
3.50%
0.37
Neuropace Inc stock is traded at $10.94, with a volume of 222.15K.
It is up +3.50% in the last 24 hours and down -38.12% over the past month.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.
See More
Previous Close:
$10.57
Open:
$10.6
24h Volume:
222.15K
Relative Volume:
0.78
Market Cap:
$388.01M
Revenue:
$65.42M
Net Income/Loss:
$-32.96M
P/E Ratio:
-8.6142
EPS:
-1.27
Net Cash Flow:
$-19.87M
1W Performance:
+3.21%
1M Performance:
-38.12%
6M Performance:
-3.61%
1Y Performance:
+59.71%
1-Day Range:
$10.27
$11.03
1-Week Range:
$9.845
$11.03
52-Week Range:
$5.45
$18.98
Neuropace Inc Stock (NPCE) Company Profile
Name
Neuropace Inc
Sector
Industry
Phone
(650) 237-2700
Address
455 N. BERNARDO AVENUE, MOUNTAIN VIEW
Compare NPCE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NPCE
Neuropace Inc
|
10.94 | 388.01M | 65.42M | -32.96M | -19.87M | -1.27 |
|
ABT
Abbott Laboratories
|
133.67 | 233.36B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
104.58 | 147.06B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
390.40 | 145.64B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
86.18 | 112.76B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.15 | 44.46B | 5.54B | 4.18B | 623.10M | 7.00 |
Neuropace Inc Stock (NPCE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-28-25 | Initiated | H.C. Wainwright | Buy |
| Jan-21-25 | Initiated | UBS | Buy |
| Mar-14-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-30-24 | Initiated | Leerink Partners | Outperform |
| Nov-10-23 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-24-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-22-23 | Initiated | Lake Street | Buy |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Jan-19-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-07-22 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-11-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-18-21 | Initiated | Robert W. Baird | Outperform |
| May-17-21 | Initiated | JP Morgan | Overweight |
| May-17-21 | Initiated | Morgan Stanley | Overweight |
| May-17-21 | Initiated | SVB Leerink | Outperform |
| May-17-21 | Initiated | Wells Fargo | Overweight |
View All
Neuropace Inc Stock (NPCE) Latest News
NeuroPace, Inc. (NPCE) Backed by Cantor Fitzgerald Following Physician Survey - MSN
Metric Analysis: NeuroPace Inc (NPCE)’s Key Ratios in the Limelight - DWinneX
NeuroPace stock rating reiterated at Overweight by Cantor Fitzgerald - Investing.com India
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc.NPCE - FinancialContent
Two Sigma Investments LP Invests $293,000 in NeuroPace, Inc. (NASDAQ:NPCE) - MarketBeat
Cantor Fitzgerald Comments on NeuroPace FY2026 Earnings - MarketBeat
Bank of America Corp DE Raises Position in NeuroPace, Inc. (NASDAQ:NPCE) - Defense World
Bronstein, Gewirtz & Grossman, LLC Is Investigating NeuroPace, Inc. (NPCE) And Encourages Shareholders to Connect - ACCESS Newswire
Research Analysts Set Expectations for NeuroPace Q2 Earnings - MarketBeat
NeuroPace Holds Virtual Annual Stockholders Meeting - TipRanks
NeuroPace’s SWOT analysis: med tech stock poised for growth amid challenges By Investing.com - Investing.com South Africa
NeuroPace’s SWOT analysis: med tech stock poised for growth amid challenges - Investing.com
NeuroPace Inc (NPCE) Shares Down 3.25% on Jun 12 - GuruFocus
Potential Securities Fraud: Levi & Korsinsky Investigates NeuroPace, Inc. (NPCE) - ACCESS Newswire
NeuroPace stock maintains buy rating at UBS following physician survey By Investing.com - Investing.com India
NeuroPace stock maintains buy rating at UBS following physician survey - Investing.com
Cantor Fitzgerald Estimates NeuroPace FY2026 Earnings - Defense World
Fraud Investigation: Levi & Korsinsky Investigates NeuroPace, Inc. (NPCE) on Behalf of Shareholders - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against NeuroPace, Inc. (NPCE) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Two Sigma Investments LP Makes New Investment in NeuroPace, Inc. (NASDAQ:NPCE) - Defense World
NeuroPace, Inc. (NPCE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
NPCE ALERT: Ongoing Investigation Into NeuroPace, Inc.Contact Levi & Korsinsky - ACCESS Newswire
Levi & Korsinsky Investigates NeuroPace, Inc. (NPCE) Over Possible Securities Fraud - ACCESS Newswire
Did NeuroPace, Inc. (NPCE) Mislead Investors? Levi & Korsinsky Investigates - ACCESS Newswire
Q2 Earnings Forecast for NeuroPace Issued By Leerink Partnrs - Defense World
Two Sigma Advisers LP Purchases New Position in NeuroPace, Inc. (NASDAQ:NPCE) - Defense World
Ongoing Investigation into NeuroPace, Inc. (NPCE): Contact Levi & Korsinsky About Potential Fraud - ACCESS Newswire
NeuroPace secures USD 75M in debt financing - Medical Buyer
BNP Paribas Financial Markets Acquires New Holdings in NeuroPace, Inc. (NASDAQ:NPCE) - Defense World
NeuroPace, Inc. (NPCE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
NeuroPace Secures $75 Million Credit Facility with MidCap - TipRanks
NeuroPace Secures $75 Million Credit Facility From MidCap Financial - marketscreener.com
NeuroPace secures $75 million credit facility with MidCap Financial - Investing.com Australia
NeuroPace secures $75 million credit facility with MidCap Financial By Investing.com - Investing.com Canada
Neuropace IncEnters Into Credit Agreement With Midcap Funding Iv Trust - MarketScreener
NeuroPace Secures Up to $75 Million in Debt Financing - The Manila Times
NeuroPace, Inc. Secures $75 Million Credit Facility from MidCap Financial to Support Growth Initiatives - Nasdaq
$75M Financing Fuels NeuroPace's Epilepsy Treatment Expansion: 5 Key Growth Initiatives Revealed - Stock Titan
Lost Money on NeuroPace, Inc. (NPCE)? Contact Levi & Korsinsky About Investigation - ACCESS Newswire
Lost Investment in NeuroPace, Inc. (NPCE)? Levi & Korsinsky Launches Securities Fraud Investigation - ACCESS Newswire
FY2028 EPS Estimates for NeuroPace Cut by Leerink Partnrs - MarketBeat
What is HC Wainwright's Forecast for NeuroPace Q2 Earnings? - MarketBeat
NPCE ACTIVE INVESTIGATION: Lost Money on NeuroPace, Inc.? Contact Levi & Korsinsky Now - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating NeuroPace, Inc. (NPCE) And Encourages Stockholders to Connect - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of NeuroPace, ... - Bluefield Daily Telegraph
Neuropace Inc Stock (NPCE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Neuropace Inc Stock (NPCE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Morrell Martha | CHIEF MEDICAL OFFICER |
Feb 21 '25 |
Sale |
13.72 |
78,334 |
1,074,844 |
81,993 |
| KCK LTD. | 10% Owner |
Feb 20 '25 |
Sale |
9.40 |
5,270,845 |
49,545,943 |
0 |
| Morrell Martha | CHIEF MEDICAL OFFICER |
Jan 30 '25 |
Sale |
15.00 |
200 |
3,000 |
86,762 |
| Morrell Martha | CHIEF MEDICAL OFFICER |
Jan 29 '25 |
Sale |
15.00 |
100 |
1,500 |
86,962 |
1.18%
0.77%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):